The Impact of Pathological Tumor Regression and Nodal Status on Survival and Systemic Disease in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

Annals of Surgical Oncology
Hiroshi MiyataYuichiro Doki

Abstract

Although tumor regression and nodal status are reported to be useful prognostic factors for patients with oesophageal cancer who are treated with neoadjuvant chemoradiotherapy, the clinical effects of those factors remain to be explained fully in neoadjuvant chemotherapy. Additionally, factor predictive of systemic disease after neoadjuvant therapy remain unexplored. The impact of pathological tumor regression and the number of involved lymph nodes on survival and the occurrence of systemic disease were examined in 405 patients with esophageal squamous cell carcinoma who received neoadjuvant chemotherapy, RESULTS: Among the 405 patients studied, 96 (23.7%) achieved good response, whereas 309 (76.3%) were classified as poor response to neoadjuvant chemotherapy. Systemic disease occurred in 136 patients (34.6%) of 393 patients who underwent curative esophagectomy. The number of involved lymph nodes and pathological tumor regression were associated with survival and the occurrence of systemic disease. Multivariate analysis showed that the number of involved lymph nodes was identified as an independent factor associated with both survival and the occurrence of systemic disease, together with the latest AJCC ypstage. However, tumor ...Continue Reading

References

Jun 7, 2002·Lancet·UNKNOWN Medical Research Council Oesophageal Cancer Working Group
Mar 23, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adam C BergerMelvyn Goldberg
Jul 11, 2006·The New England Journal of Medicine·David Cunningham MAGIC Trial Participants
Mar 3, 2007·The Lancet Oncology·Val GebskiUNKNOWN Australasian Gastro-Intestinal Trials Group
Apr 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurent BedenneChristine Binquet
Apr 26, 2007·Annals of Surgery·John Vincent ReynoldsThomas J Murphy
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David P KelsenUNKNOWN USA Intergroup
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel TepperRobert Mayer
Nov 19, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Bryan H BurmeisterB Mark Smithers
Mar 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc YchouPhilippe Rougier
Jun 1, 2012·The New England Journal of Medicine·P van HagenUNKNOWN CROSS Group
Jan 15, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vera OppedijkMaarten C C M Hulshof
Jul 2, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe MarietteJean-François Seitz
Nov 2, 2014·Annals of Surgery·William B RobbUNKNOWN Fédération Française de Cancérologie Digestive, Société Française de Radiothérapie Oncologique, Union des Centres de Lutte C
Jan 20, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F KlevebroM Nilsson
Apr 5, 2016·The British Journal of Surgery·S BekkarUNKNOWN French Eso-Gastric Tumors (FREGAT) working group, Fédération de Recherche EN CHirurgie (FRENCH) and Association Française de
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth C SmythNicola Valeri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.